Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
active malignancy
hypersensitivity to tesamorelin |
| gptkbp:dosage_form |
lyophilized powder for reconstitution
|
| gptkbp:effective_date |
2010-11-10
|
| https://www.w3.org/2000/01/rdf-schema#label |
Egrifta
|
| gptkbp:indication |
excess abdominal fat in HIV-infected patients
|
| gptkbp:ingredients |
tesamorelin
|
| gptkbp:manufacturer |
Theratechnologies
|
| gptkbp:mechanism_of_action |
growth hormone-releasing factor analog
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:side_effect |
headache
nausea diarrhea injection site reactions |
| gptkbp:storage |
refrigerated at 2-8° C
|
| gptkbp:used_for |
treatment of HIV-associated lipodystrophy
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
|
| gptkbp:bfsLayer |
5
|